Rajat Bannerji, MD, PhD, Rutgers Cancer Institute of New Jersey, NJ, discusses the updated results of the Phase I study (NCT02290951) aiming to evaluate the efficacy and safety of odronextamab (REGN1979) in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHL). No dose-limiting toxicities (DLTs) were reported during dose escalation and the maximum tolerated dose was not reached. While treatment-emergent adverse events occurred in most patients, none of them required treatment discontinuation. In patients with R/R follicular lymphoma, odronextamab demonstrated significant therapeutic activity. In R/R diffuse large B-cell lymphoma patients, encouraging activity was observed at higher dose levels, especially in patients with no history of CAR-T treatment. With clear clinical activity and an acceptable safety profile, these findings suggest that odronextamab has potential as a novel single-agent treatment in R/R B-NHLs, including in patients refractory to CAR-T therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Rajat Bannerji, MD, PhD, has received research funding from Regeneron Pharmaceuticals, AbbVie, F. Hoffman-La Roche Ltd/Genentech, Inc. and Pharmacyclics LLC, an AbbVie company. Dr Bannerji’s spouse is an employee of Sanofi-Pasteur.